Center for Biologics Evaluation and Research, except as provided in paragraph (c)(2) of this section. Official release is required for at least five consecutive lots or fillings, as applicable, manufactured after licensure of the product.

(2) After written notification of official release is received from the Director, Center for Biologics Evaluation and Research, for at least five consecutive lots or fillings manufactured after licensure of the products, and after the manufacturer receives from the Director, Center for Biologics Evaluation and Research, written notification that official release is no longer required, subsequent lots or fillings may be released by the manufacturer under the requirements of §610.1 of this chapter.

(3) The manufacturer shall not distribute lots or fillings, as applicable, of products that require sample submission under paragraph (a)(2)(iii) of this section until written notification of official release or notification that official release is no longer required is received from the Director, Center for Biologics Evaluation and Research.

\[50\ FR\ 5579,\ Feb. 11,\ 1985,\ as\ amended\ at\ 50\ FR\ 16474,\ Apr. 26,\ 1985;\ 65\ FR\ 77499,\ Dec. 12,\ 2000;\ 67\ FR\ 9587,\ Mar. 4,\ 2002\]

**Subpart F—Anti-Human Globulin**

§ 660.50 Anti-Human Globulin.

(a) Proper name and definition. The proper name of this product shall be Anti-Human Globulin which shall consist of one or more antiglobulin antibodies identified in §660.55(d).

(b) Source. The source of this product shall be either serum from animals immunized with one or more human serum globulins or protein-rich fluids derived from stable immunoglobulin-secreting cell lines maintained either in tissue cultures or in secondary hosts.

\[50\ FR\ 5579,\ Feb. 11, 1985,\ as\ amended\ at\ 65\ FR\ 77499,\ Dec. 12, 2000\]

§ 660.51 Processing.

(a) Processing method. (1) The processing method shall be one that has been shown to yield consistently a specific, potent final product, free of properties that would adversely affect the product for its intended use throughout its dating period.

(2) Anti-IgG, –C3d (polyspecific) reagents and anti-IgG products may be colored green.

(3) Only that material which has been fully processed, thoroughly mixed in a single vessel, and filtered shall constitute a lot. Each lot shall be identified by a lot number.

(4) A lot may be subdivided into sublots which shall be identified by the lot number to which has been added a distinctive prefix or suffix. If lots are to be subdivided, the manufacturer shall include this information in the license application. The manufacturer shall describe the test specifications to verify that each sublot is identical to other sublots of the lot.

(b) Final containers and dropper assemblies. (1) Final containers and dropper assemblies shall be clean.

(2) Final containers and dropper pipettes shall be colorless and sufficiently transparent to permit observation of the contents for presence of particulate matter or increased turbidity.

(c) Date of manufacture. The date of manufacture shall be the date the manufacturer begins the last entire group of potency tests.

\[50\ FR\ 5579,\ Feb. 11,\ 1985,\ as\ amended\ at\ 50\ FR\ 16474,\ Apr. 26,\ 1985;\ 65\ FR\ 77499,\ Dec. 12, 2000;\ 67\ FR\ 9587,\ Mar. 4,\ 2002\]

§ 660.52 Reference preparations.

Reference Anti-Human Globulin preparations shall be obtained from the Center for Biologics Evaluation and Research (HFM–407) (see mailing addresses in §600.2 of this chapter), and shall be used as described in the accompanying package insert for determining the potency of Anti-Human Globulin.

\[50\ FR\ 5579,\ Feb. 11,\ 1985,\ as\ amended\ at\ 50\ FR\ 16474,\ Apr. 26,\ 1985;\ 51\ FR\ 15611,\ Apr. 25, 1986;\ 55\ FR\ 11013\ and\ 11014,\ Mar. 26, 1990;\ 70\ FR\ 14986,\ Mar. 24, 2005\]

§ 660.53 Controls for serological procedures.

Red blood cells sensitized with complement shall be tested with appropriate positive and negative control antisera. All tests shall be performed in accordance with serological testing...